"As always, we welcome your feedback on this issue. " Sound familiar? It should -this is all too oft en the closing sentence of this journal's Editorial. But perhaps we should clarify that it is not merely a space-fi ller being used in the absence of anything more substantive to say. We do mean it.
Th e second week of each month, our offi ce becomes that bit more frantic as we work to get the issue fi nished and off to the printers. Once the piles of journals arrive back, fresh off the press, we wonder what the community will make of the content within its pages. Will they be convinced and excited by the new research being published? What might they think of opinions put forward in the News and Views? Will they agree with our editorial viewpoints? We wait with bated breath but, month aft er month, very little happens. Noone, it seems, has anything to say. Or, more likely, people have plenty to say but neither the time nor the inclination to put fi nger to keyboard and tell us about it.
Our Correspondence section has always been intended as a forum for discussion of the content we have recently published, but importantly, also the wider issues in the fi eld. Particularly at this time, with molecular and cellular biology directly impinging on several intricate ethical issues, from stem cells to gene technology, we feel it is imperative that researchers discuss these topics openly with the community. Th is is particularly true given that researchers are held to more intense public scrutiny these days.
So far, our Correspondence section has been put to limited use, predominantly being used for the publication of refutations. In contrast to some other journals, we think that refutations are a key part of the scientifi c process, and we are happy to publish these so long as they make a defi nitive point supported by data that stands up to the usual stringent criteria of this journal. In our mind, there are two types of refutation. Th e fi rst is when researchers have done almost exactly the same experiment and come to a diff erent conclusion to that published in an NCB paper. On occasion, this may even lead to the retraction of the original paper. Th e second, which forms the bulk of refutations in our experience, is instances where another group has come to inconsistent conclusions based on their related experiments (for example, using another system or experimental aproach).
In each case, the procedure is this: we give the authors of the original study the option to respond, providing their explanation for the basis of the discrepancy. Both the refutation and the response are then fully peer reviewed, usually by the original reviewers. Should the reviewers fi nd the data or arguments convincing, we may publish the refutation with or without the response in our Correspondence section (see our April 2005 issue for a recent example). As always, each refutation and the response is published, or not, on the basis of its own merit. Th ese are considered to be bona fi de publications and, as such, are cited on PubMed. Oft en, the reason for diff ering conclusions cannot always be explained fully, but we hope that by publishing the observations, readers can come to their own conclusions and further studies can be instigated to move the fi eld forward.
Beyond refutations, we continue to hope that this section will also provide a means for researchers to write in about whatever is on their mind, be it issues pertinent to cell biology and society, the funding and publishing process, or developing research trends within the fi eld. Th ere are few printed forums that allow ongoing discussions of key issues in cell biology, so we hope you will make use of this one. As always, we welcome ….
EU basic research spending plans take shape
On 6 April, the European Commission adopted the Seventh Research Framework Programme (FP7), set to run 2007-2013 (http://europa. eu.int/rapid/pressReleasesAction.do). Aft er a signifi cant consultation exercise last year, the thematic priorities of the previous framework programme remain largely unchanged. Although there is a continued emphasis on support for research that is relevant to industry and for trans-European cooperation, two changes stand out. First, the European Research Council (ERC) has fi nally been given the goahead as an autonomous institution, with the stated aim of enhancing the quality of basic research. Second, there is an explicit emphasis on scientifi c excellence achieved through competition and peer review. However, this apparent shift to a more merit-based awards policy is dampened by the fact that of the overall budget of almost €68 billion, only one-fi ft h (€10.5 billion) is earmarked for distribution by the ERC, compared with €39.2 billion for cooperative research initiatives. Whereas the total budget has doubled, the actual rise is not as pronounced, because the money is spread over seven years, rather than four, as previously. Nevertheless, this extended funding period provides much needed continuity for large multinational research programmes.
Of course, the proposal is yet to be debated by the council of member states and the European Parliament. Although the proposal is likely to pass at parliament level, a concern is that several council members, particularly those facing federal defi cits, will erode the budget -either directly, or by reducing domestic research spending. Th e proposed European research budget represents less than 10% of R&D spending within the European Union (or 0.1% of EU GDP) and it would be lamentable if this programme, which is clearly heading in the right direction on several fronts, had the wind taken out of its sails. To ensure the long-term viability of Europe as a knowledge-based economy, spending on basic research must continue to grow in real terms.
